All this suggests that it is unlikely that JMJD2D impinges in a meaningful way on the oncogenic potential of prostate cancer cells through modulating the expression of GLIS3, RSPO3, NPR1 or OSR2. The gene discussed is OSR2; the disease is prostate carcinoma.